1. Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST) 
M Ranucci, E Baryshnikova 
British Journal of Anaesthesia 
Volume 116, Issue 5, Pages (May 2016)
DOI: /bja/aev539
Copyright © 2016 The Author(s) Terms and Conditions

2. Fig 1
Linear regression analyses for association between FIBTEM maximum clot firmness (MCF) and Clauss fibrinogen concentration. (a) Overall population. (b) Separate analysis for supplemented and unsupplemented subjects. Blue dots: unsupplemented subjects; green triangles: supplemented subjects.
British Journal of Anaesthesia  , DOI: ( /bja/aev539)
Copyright © 2016 The Author(s) Terms and Conditions

3. Fig 2
Receiver operating characteristics analysis for (a) FIBTEM MCF and (b) Clauss fibrinogen concentration. Outcome variable: severe bleeding. FIBTEM MCF values after placebo or fibrinogen administration; Clauss values upon arrival in the intensive care unit. n+116. AUC: area under the curve.
British Journal of Anaesthesia  , DOI: ( /bja/aev539)
Copyright © 2016 The Author(s) Terms and Conditions

4. Fig 3
Difference between expected (22 mm) and observed FIBTEM maximum clot firmness (MCF) after fibrinogen concentrate supplementation.
British Journal of Anaesthesia  , DOI: ( /bja/aev539)
Copyright © 2016 The Author(s) Terms and Conditions

5. Fig 4
Linear regression analysis for association between fibrinogen concentrate dose and increase in FIBTEM maximum clot firmness (MCF) after dosing.
British Journal of Anaesthesia  , DOI: ( /bja/aev539)
Copyright © 2016 The Author(s) Terms and Conditions